A Multicenter, Randomized, Double-Blind, Crossover Study of Patient Preference for Tadalafil 20 mg or Sildenafil Citrate 50 mg During Initiation of Treatment for Erectile Dysfunction

Clinical Therapeutics

Volumn 25, Issue 11, 2003, Pages 2709-2723

  Govier, Fred ^a   Potempa, Axel Juerg ^b   Kaufman, Joel ^c   Denne, Jonathan ^d   Kovalenko, Pavel ^d   Ahuja, Sanjeev ^d  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b Private Practice   (Germany)

^c Urology Research Options   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Drug therapy; Erectile dysfunction; Sildenafil; Tadalafil

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; TADALAFIL;

ADULT; AGE; ARTICLE; CHRONOSEQUENCE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EXPOSURE; DRUG THERAPY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; EYELID EDEMA; FLUSHING; GERMANY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; PATIENT ATTITUDE; PATIENT PREFERENCE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT INITIATION; UNITED STATES; VISUAL IMPAIRMENT;

EID: 0345095481     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80328-4     Document Type: Article

References (28)

1. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res. 2000;12(Suppl 4):S6-S11.
2. Litwin MS, Nied RJ, Dhanani N. Health-related quality of life in men with erectile dysfunction. J Gen Intern Med. 1998;13:159-166.
3. Rust J, Golombok S, Collier J. Marital problems and sexual dysfunction: How are they related? Br J Psychiatry. 1988;152:629-631.
4. NIH Consensus Development Panel on Impotence. NIH Consensus Conference. Impotence. JAMA. 1993;270:83-90.
5. Wagner G, Fugl-Meyer KS, Fugl-Meyer AR. Impact of erectile dysfunction on quality of life: Patient and partner perspectives. Int J Impot Res. 2000;12(Suppl 4):S144-S146.
6. Aytaç IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50-56.
7. Burchardt M, Burchardt T, Anastasiadis AG, et al. Erectile dysfunction is a marker for cardiovascular complications and psychological functioning in men with hypertension. Int J Impot Res. 2001;13:276-281.
8. Kirby M, Jackson G, Betteridge J, Friedli K. Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Pract. 2001;55:614-618.
9. Buvat J, Lemaire A, Buvat-Herbaut M, et al. Comparative investigations in 26 impotent and 26 nonimpotent diabetic patients. J Urol. 1985;133:34-38.
10. O'Kane PD, Jackson G. Erectile dysfunction: Is there silent obstructive coronary artery disease? Int J Clin Pract. 2001;55:219-220.
11. Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 1992;326:90-94.
12. Hanash KA. Comparative results of goal oriented therapy for erectile dysfunction. J Urol. 1997;157:2135-2138.
13. Jarow JP, Nana-Sinkam P, Sabbagh M, Eskew A. Outcome analysis of goal directed therapy for impotence. J Urol. 1996;155:1609-1612.
14. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil in the treatment of erectile dysfunction: Results of integrated analyses. J Urol. 2002;168:1332-1336.
15. Sildenafil citrate [package insert]. New York: Pfizer Inc; 2001.
16. Fink HA, Mac Donald R, Rutks IR, et al. Sildenafil for male erectile dysfunction: A systematic review and meta-analysis. Arch Intern Med. 2002;162:1349-1360.
17. Morales A, Gingell C, Collins M, et al. Clinical safety of oral sildenafil citrate (VIAGRA™) in the treatment of erectile dysfunction. Int J Impot Res. 1998;10:69-73.
18. Padma-Nathan H. Diagnostic and treatment strategies for erectile dysfunction: The 'Process of Care' model [University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School]. Int J Impot Res. 2000;12(Suppl 4):S119-S121.
19. Hanson-Divers C, Jackson SE, Lue TF, et al. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol. 1998;159:1541-1547.
20. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol. 1999;162:722-725.
21. Hatzichristou DG, Apostolidis A, Tzortzis V, et al. Sildenafil versus intracavernous injection therapy: Efficacy and preference in patients on intracavernous injection for more than 1 year. J Urol. 2000;164:1197-1200.
22. McMahon CG, Samali R, Johnson H. Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. J Urol. 2000;164:1192-1196.
23. Giuliano F, Montorsi F, Mirone V, et al. Switching from intracavernous prostaglandin El injections to oral sildenafil citrate in patients with erectile dysfunction: Results of a multicenter European study. J Urol. 2000;164:708-711.
24. Fagelman E, Fagelman A, Shabsigh R. Efficacy, safety, and use of sildenafil in urologic practice. Urology. 2001;57:1141-1144.
25. Martinez-Jabaloyas JM, Gil-Salom M, Villamon-Fort R, et al. Prognostic factors for response to sildenafil in patients with erectile dysfunction. Eur Urol. 2001;40:641-646.
26. Paige NM, Hays RD, Litwin MS, et al. Improvement in emotional well-being and relationships of users of sildenafil. J Urol. 2001;166:1774-1778.
27. Marks LS, Duda C, Dorey FJ, et al. Treatment of erectile dysfunction with sildenafil. Urology. 1999;53:19-24.
28. Wagner G, Montorsi F, Auerbach S, Collins M. Sildenafil citrate (Viagra®) improves erectile function in elderly patients with erectile dysfunction: A subgroup analysis. J Gerontol A Biol Sci Med Sci. 2001;56:M113-M119.